{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:08:30Z","timestamp":1790341710283,"version":"4.1.0"},"reference-count":236,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has prompted a massive global vaccination campaign, leading to the rapid development and deployment of several vaccines. Various COVID-19 vaccines are under different phases of clinical trials and include the whole virus or its parts like DNA, mRNA, or protein subunits administered directly or through vectors. Beginning in 2020, a few mRNA (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and adenovirus-based (AstraZeneca ChAdOx1-S and the Janssen Ad26.COV2.S) vaccines were recommended by WHO for emergency use before the completion of the phase 3 and 4 trials. These vaccines were mostly administered in two or three doses at a defined frequency between the two doses. While these vaccines, mainly based on viral nucleic acids or protein conferred protection against the progression of SARS-CoV-2 infection into severe COVID-19, and prevented death due to the disease, their use has also been accompanied by a plethora of side effects. Common side effects include localized reactions such as pain at the injection site, as well as systemic reactions like fever, fatigue, and headache. These symptoms are generally mild to moderate and resolve within a few days. However, rare but more serious side effects have been reported, including allergic reactions such as anaphylaxis and, in some cases, myocarditis or pericarditis, particularly in younger males. Ongoing surveillance and research efforts continue to refine the understanding of these adverse effects, providing critical insights into the risk-benefit profile of COVID-19 vaccines. Nonetheless, the overall safety profile supports the continued use of these vaccines in combating the pandemic, with regulatory agencies and health organizations emphasizing the importance of vaccination in preventing COVID-19\u2019s severe outcomes. In this review, we describe different types of COVID-19 vaccines and summarize various adverse effects due to autoimmune and inflammatory response(s) manifesting predominantly as cardiac, hematological, neurological, and psychological dysfunctions. The incidence, clinical presentation, risk factors, diagnosis, and management of different adverse effects and possible mechanisms contributing to these effects are discussed. The review highlights the potential ambivalence of human response post-COVID-19 vaccination and necessitates the need to mitigate the adverse side effects.<\/jats:p>","DOI":"10.3390\/biom14101320","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T08:56:32Z","timestamp":1729155392000},"page":"1320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Ambivalence of Post COVID-19 Vaccination Responses in Humans"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8688-4617","authenticated-orcid":false,"given":"Radha","family":"Gopalaswamy","sequence":"first","affiliation":[{"name":"Directorate of Distance Education, Madurai Kamaraj University, Madurai 625021, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-4948","authenticated-orcid":false,"given":"Vivekanandhan","family":"Aravindhan","sequence":"additional","affiliation":[{"name":"Department of Genetics, Dr Arcot Lakshmanasamy Mudaliyar Post Graduate Institute of Basic Medical Sciences (Dr ALM PG IBMS), University of Madras, Taramani, Chennai 600005, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-8632","authenticated-orcid":false,"given":"Selvakumar","family":"Subbian","sequence":"additional","affiliation":[{"name":"Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, September 15). WHO COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c."},{"key":"ref_2","unstructured":"Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., and Di Napoli, R. (2024). Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00508-020-01760-4","article-title":"Clinical manifestations of COVID-19 in the general population: Systematic review","volume":"133","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mathew, D.S., Pandya, T., Pandya, H., Vaghela, Y., and Subbian, S. (2023). An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines. Biomolecules, 13.","DOI":"10.3390\/biom13111565"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ramasamy, S., and Subbian, S. (2021). Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin. Microbiol. Rev., 34.","DOI":"10.1128\/CMR.00163-21"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Beijnen, E.M.S., Odumade, O.A., and Haren, S.D.V. (2023). Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. Vaccines, 11.","DOI":"10.3390\/vaccines11030509"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., and Zhao, B. (2022). Allergic Reactions afterthe Administration of COVID-19 Vaccines. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.878081"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1148\/rg.2020200159","article-title":"Chest CT in COVID-19: What the Radiologist Needs to Know","volume":"40","author":"Kwee","year":"2020","journal-title":"Radiographics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4314\/gmj.v54i4s.14","article-title":"CT scan chest findings in symptomatic COVID-19 patients: A reliable alternative for diagnosis","volume":"54","author":"Sarkodie","year":"2020","journal-title":"Ghana. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.12688\/f1000research.75311.1","article-title":"Quantitative image analysis in COVID-19 acute respiratory distress syndrome: A cohort observational study","volume":"10","author":"Dolinay","year":"2021","journal-title":"F1000Research"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kang, D.H., Kim, G.H.J., Park, S.B., Lee, S.I., Koh, J.S., Brown, M.S., Abtin, F., McNitt-Gray, M.F., Goldin, J.G., and Lee, J.S. (2024). Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010120"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Banerjee, S., Banerjee, D., Singh, A., Kumar, S., Pooja, D., Ram, V., Kulhari, H., and Saharan, V.A. (2023). A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. Vaccines, 11.","DOI":"10.3390\/vaccines11020332"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Rigopoulos, E.A., Kaiafa, G., Daios, S., Karlafti, E., Ztriva, E., Polychronopoulos, G., Gogos, C., and Savopoulos, C. (2022). Tixagevimab\/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. Viruses, 15.","DOI":"10.3390\/v15010118"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiac320","article-title":"Casirivimab and Imdevimab for the Treatment of Hospitalized Patients with COVID-19","volume":"227","author":"Mylonakis","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-023-40204-1","article-title":"Monoclonal antibody levels and protection from COVID-19","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12985-020-01369-z","article-title":"SARS-CoV-2: Characteristics and current advances in research","volume":"17","author":"Yang","year":"2020","journal-title":"Virol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1202504","DOI":"10.3389\/fmed.2023.1202504","article-title":"Corticosteroids in COVID-19: Pros and cons","volume":"10","author":"Bahsoun","year":"2023","journal-title":"Front Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gopalaswamy, R., and Subbian, S. (2021). Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073773"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, X., Mi, Z., Liu, Z., and Rong, P. (2024). SARS-CoV-2: Pathogenesis, therapeutics, variants, and vaccines. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1334152"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M.E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., and Rezza, G. (2022). COVID-19 Vaccines: Current and Future Perspectives. Vaccines, 10.","DOI":"10.3390\/vaccines10040608"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08830185.2022.2079642","article-title":"SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies","volume":"42","author":"Gong","year":"2023","journal-title":"Int. Rev. Immunol."},{"key":"ref_24","first-page":"CD015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Grana","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2002083","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rotshild, V., Hirsh-Raccah, B., Miskin, I., Muszkat, M., and Matok, I. (2021). Comparing the clinical efficacy of COVID-19 vaccines: A systematic review and network meta-analysis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02321-z"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wu, X., Xu, K., Zhan, P., Liu, H., Zhang, F., Song, Y., and Lv, T. (2024). Comparative efficacy and safety of COVID-19 vaccines in phase III trials: A network meta-analysis. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-023-08754-3"},{"key":"ref_28","unstructured":"WHO (2024, September 15). World Health Organization (WHO) 12 Vaccines Granted Emergency Use Listing (EUL) by WHO. Available online: https:\/\/covid19.trackvaccines.org\/agency\/who\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e23937","DOI":"10.1002\/jcla.23937","article-title":"Analysis of COVID-19 vaccines: Types, thoughts, and application","volume":"35","author":"Han","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, Y.D., Chi, W.Y., Su, J.H., Ferrall, L., Hung, C.F., and Wu, T.C. (2020). Coronavirus vaccine development: From SARS and MERS to COVID-19. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-020-00695-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/08971900221097248","article-title":"The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses","volume":"36","author":"Muhar","year":"2023","journal-title":"J. Pharm. Pract."},{"key":"ref_32","unstructured":"WHO (2024, September 15). Interim Recommendations for Use of the Moderna mRNA-1273 Vaccine against COVID-19: Interim Guidance. 25 January 2021. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.3."},{"key":"ref_33","unstructured":"WHO (2024, September 15). Interim Recommendations for Use of the Pfizer\u2013BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing: Interim Guidance. 8 January 2021. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1."},{"key":"ref_34","unstructured":"WHO (2024, September 15). Interim Recommendations for the Use of the Janssen Ad26.COV2.S. Available online: https:\/\/iris.who.int\/handle\/10665\/340203."},{"key":"ref_35","unstructured":"WHO (2024, September 15). Interim Recommendations for Use of the ChAdOx1-S Vaccine against COVID-19. Available online: https:\/\/iris.who.int\/handle\/10665\/343388."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fayad, D., and Frenck, R.W. (2023). COVID-19 Vaccines in Children. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010087"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"CDC (2024, September 15). COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months\u20134 Years\u2014United States, 20 June \u201331 December 2022, Available online: https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7207a4.htm.","DOI":"10.15585\/mmwr.mm7207a4"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.puhe.2024.01.029","article-title":"Child and adolescent COVID-19 vaccination coverage by educational setting, United States","volume":"229","author":"Nguyen","year":"2024","journal-title":"Public Health"},{"key":"ref_39","unstructured":"CDC (2024, September 15). COVID-19 Vaccination for People Who Are Pregnant or Breastfeeding, Available online: https:\/\/www.cdc.gov\/covid\/vaccines\/pregnant-or-breastfeeding.html."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"AbdelWareth, L., Alhousani, F., Abuyadek, R., Donnelly, J., Leinberger-Jabari, A., Atef, S., and Al-Rifai, R.H. (2023). Natural infection versus hybrid (natural and vaccination) humoral immune response to SARS-CoV-2: A comparative paired analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1230974"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Suntronwong, N., Kanokudom, S., Auphimai, C., Thongmee, T., Assawakosri, S., Vichaiwattana, P., Yorsaeng, R., Duangchinda, T., Chantima, W., and Pakchotanon, P. (2024). Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection. Vaccines, 12.","DOI":"10.3390\/vaccines12020180"},{"key":"ref_43","unstructured":"WHO (2024, September 15). Interim Statement on Hybrid Immunity and Increasing Population Seroprevalence Rates. Available online: https:\/\/www.who.int\/news\/item\/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates."},{"key":"ref_44","first-page":"397","article-title":"Case of localized form of respiratory tract amyloidosis with double localization","volume":"27","author":"Kulczynski","year":"1973","journal-title":"Otolaryngol. Pol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse Events Reported fromCOVID-19 Vaccine Trials: A Systematic Review","volume":"36","author":"Kaur","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_46","unstructured":"CDC (2024, September 15). Vaccine Safety System, Available online: https:\/\/www.cdc.gov\/vaccine-safety-systems\/index.html."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rafaniello, C., Gaio, M., Zinzi, A., Sullo, M.G., Liguori, V., Ferraro, M., Petronzelli, F., Felicetti, P., Marchione, P., and Marra, A.R. (2022). Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050525"},{"key":"ref_48","first-page":"44","article-title":"COVID-19 Vaccine-induced Myocarditis","volume":"13","author":"Munjal","year":"2023","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Guo, W., Deguise, J., Tian, Y., Huang, P.C., Goru, R., Yang, Q., Peng, S., Zhang, L., Zhao, L., and Xie, J. (2022). Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.870599"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Alami, A., Villeneuve, P.J., Farrell, P.J., Mattison, D., Farhat, N., Haddad, N., Wilson, K., Gravel, C.A., Crispo, J.A.G., and Perez-Lloret, S. (2023). Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective. J. Clin. Med., 12.","DOI":"10.3390\/jcm12154971"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/jmv.27940","article-title":"Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials","volume":"94","author":"Tian","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1016\/j.vaccine.2023.03.038","article-title":"Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis","volume":"41","author":"Ciapponi","year":"2023","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41541-023-00698-8","article-title":"Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis","volume":"8","author":"Marchand","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jama.2023.26945","article-title":"Neonatal Outcomes afterCOVID-19 Vaccination in Pregnancy","volume":"331","author":"Norman","year":"2024","journal-title":"JAMA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2589-7500(23)00093-6","article-title":"Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: A retrospective cohort study","volume":"5","author":"Piekos","year":"2023","journal-title":"Lancet Digit. Health"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Goruntla, N., Karisetty, B., Nandini, N., Bhupasamudram, B., Gangireddy, H.R., Veerabhadrappa, K.V., Ezeonwumelu, J.O.C., and Bandaru, V. (2023). Adverse events following COVID-19 vaccination among pregnant women attending primary health centers: An active-surveillance study. Vacunas, ahead of print.","DOI":"10.1016\/j.vacun.2023.05.003"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/08971900231196065","article-title":"Systematic Review: Safety and Efficacy of mRNA COVID-19 Vaccines in Pregnant Women","volume":"37","author":"Lam","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","article-title":"Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2, randomised trial","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): A single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"key":"ref_61","first-page":"2504","article-title":"Side Effects after mRNA COVID-19 Vaccine as a Booster in Health Workers","volume":"51","author":"Pakki","year":"2022","journal-title":"Iran. J. Public Health"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hung, S.I., Preclaro, I.A.C., Chung, W.H., and Wang, C.W. (2022). Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061260"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaci.2022.09.003","article-title":"Management of patients with immediate reactions to COVID-19 vaccines","volume":"151","author":"Picard","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_65","unstructured":"Control, C.f.D. (2024, September 15). Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/managing-anaphylaxis.html."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Laisuan, W. (2021). COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches. Front. Allergy, 2.","DOI":"10.3389\/falgy.2021.801322"},{"key":"ref_67","unstructured":"Control, C.F.D. (2024, September 15). Recognizing and Responding to Anaphylaxis, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/106312."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: A meta-analysis","volume":"20","author":"Sobczak","year":"2022","journal-title":"Clin. Mol. Allergy"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Boufidou, F., Hatziantoniou, S., Theodoridou, K., Maltezou, H.C., Vasileiou, K., Anastassopoulou, C., Medic, S., and Tsakris, A. (2023). Anaphylactic Reactions to COVID-19 Vaccines: An Updated Assessment Based on Pharmacovigilance Data. Vaccines, 11.","DOI":"10.3390\/vaccines11030613"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: A review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/cea.13822","article-title":"Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients","volume":"51","author":"Johansen","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Swetha, K., Kotla, N.G., Tunki, L., Jayaraj, A., Bhargava, S.K., Hu, H., Bonam, S.R., and Kurapati, R. (2023). Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines, 11.","DOI":"10.20944\/preprints202302.0142.v1"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41578-021-00379-9","article-title":"From lipids to lipid nanoparticles to mRNA vaccines","volume":"6","author":"Horejs","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Nicaise-Roland, P., Granger, V., Soria, A., Barbaud, A., Pallardy, M., Chollet-Martin, S., and de Chaisemartin, L. (2022). Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis. Front. Allergy, 3.","DOI":"10.3389\/falgy.2022.1007602"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40259-022-00536-8","article-title":"Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","article-title":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing COVID-19 vaccines: Evidence for immunogenicity of PEG","volume":"41","author":"Kozma","year":"2023","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","volume":"147","author":"Risma","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ndeupen, S., Qin, Z., Jacobsen, S., Estanbouli, H., Bouteau, A., and Igyarto, B.Z. (2021). The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. bioRxiv, 24.","DOI":"10.1101\/2021.03.04.430128"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12026-023-09357-5","article-title":"COVID-19 vaccines adverse events: Potential molecular mechanisms","volume":"71","author":"Lamprinou","year":"2023","journal-title":"Immunol. Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kounis, N.G., Koniari, I., de Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S.F., Gogos, C., Kouni, S.N., and Kounis, G.N. (2021). Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines, 9.","DOI":"10.3390\/vaccines9030221"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/geronj\/42.3.329","article-title":"Does the brain age uniformly? Evidence from effects of smooth pursuit eye movements on verbal and visual tasks","volume":"42","author":"Lapidot","year":"1987","journal-title":"J. Gerontol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehaa664","article-title":"Pathological features of COVID-19-associated myocardial injury: A multicentre cardiovascular pathology study","volume":"41","author":"Basso","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4470326","DOI":"10.1155\/2024\/4470326","article-title":"The Epidemiology of COVID-19 Vaccine-Induced Myocarditis","volume":"2024","author":"Costa","year":"2024","journal-title":"Adv. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s11886-022-01801-6","article-title":"COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation","volume":"24","author":"Furqan","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/qjmed\/hcac064","article-title":"Myocarditis post-SARS-CoV-2 vaccination: A systematic review","volume":"116","author":"Goyal","year":"2023","journal-title":"QJM"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4070\/kcj.2024.0065","article-title":"COVID-19 Vaccination-Related Myocarditis: What We Learned fromOur Experience and What We Need to Do in The Future","volume":"54","author":"Park","year":"2024","journal-title":"Korean Circ. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20420986241226566","DOI":"10.1177\/20420986241226566","article-title":"Determinants of COVID-19 vaccine-induced myocarditis","volume":"15","author":"Rose","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/hematolrep14040050","article-title":"COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes","volume":"14","author":"Allas","year":"2022","journal-title":"Hematol. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.16885","article-title":"Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19)","volume":"190","author":"Chen","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.2022017696","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"141","author":"Cines","year":"2023","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ejh.13855","article-title":"COVID-19: Vaccine-induced immune thrombotic thrombocytopenia","volume":"109","author":"Danish","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2022.03.034","article-title":"Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis","volume":"119","author":"Kim","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.tru.2021.100086","article-title":"Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices","volume":"5","author":"Swan","year":"2021","journal-title":"Thromb. Update"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/bmj.326.7403.1358","article-title":"Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis","volume":"326","author":"Wong","year":"2003","journal-title":"BMJ"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Bissola, A.L., Treverton, J., Hack, M., Lychacz, M., Kwok, S., Arnold, A., and Nazy, I. (2024). Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders. J. Clin. Med., 13.","DOI":"10.20944\/preprints202312.1578.v1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e2253845","DOI":"10.1001\/jamanetworkopen.2022.53845","article-title":"Reports of Guillain-Barre Syndrome afterCOVID-19 Vaccination in the United States","volume":"6","author":"Abara","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"108183","DOI":"10.1016\/j.clineuro.2024.108183","article-title":"Guillain-Barre syndrome after COVID-19 vaccination: A systematic review and analysis of case reports","volume":"238","author":"Abuawwad","year":"2024","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Alijanzadeh, D., Soltani, A., Afra, F., Salmanpour, F., Loghman, A.H., Samieefar, N., and Rezaei, N. (2023). Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: A systematic review of case studies. BMC Neurol., 23.","DOI":"10.1186\/s12883-023-03375-4"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ane.13550","article-title":"Neurological side effects of SARS-CoV-2 vaccinations","volume":"145","author":"Finsterer","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Hadhiah, K., Alhashim, A., Al-Dandan, H.A., Alhassan, E., Alqarni, A.M., Memish, A.A.A., and Alabdali, M. (2024). Guillain-Barre syndrome post-SARS-CoV-2 vaccine: A systematic review and data analysis on its clinical, laboratory, electrophysiological, and radiological features. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1332364"},{"key":"ref_105","first-page":"e37578","article-title":"Guillain-Barre Syndrome Induced by Vaccination against COVID-19: A Systematic Review and Meta-Analysis","volume":"15","author":"Ogunjimi","year":"2023","journal-title":"Cureus"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Rzymski, P. (2023). Guillain-Barre syndrome and COVID-19 vaccines: Focus on adenoviral vectors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1183258"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Yu, M., Nie, S., Qiao, Y., and Ma, Y. (2023). Guillain-Barre syndrome following COVID-19 vaccines: A review of literature. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1078197"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10072-021-05776-0","article-title":"Miller Fisher syndrome following Pfizer COVID-19 vaccine","volume":"43","author":"Abicic","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ane.13687","article-title":"Miller Fisher syndrome following COVID-19 vaccines: A scoping review","volume":"146","author":"Kim","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2125753","DOI":"10.1080\/21645515.2022.2125753","article-title":"Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review","volume":"18","author":"Liang","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_111","first-page":"e43111","article-title":"Miller Fisher Syndrome Associated With COVID-19: A History of Molecular Mimicry and an Up-to-Date Review of the Literature","volume":"15","author":"Poyraz","year":"2023","journal-title":"Cureus"},{"key":"ref_112","first-page":"1615","article-title":"Diagnosis and Management of Myasthenia Gravis","volume":"28","author":"Hehir","year":"2022","journal-title":"Continuum"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/01676830.2022.2062777","article-title":"Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine","volume":"42","author":"Maher","year":"2023","journal-title":"Orbit"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Mirmosayyeb, O., Moases Ghaffary, E., Mazdak, M., Bagheri, Z., Bagherieh, S., and Shaygannejad, V. (2022). Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review. Can. J. Infect. Dis. Med. Microbiol., 2022.","DOI":"10.1155\/2022\/5009450"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Tayebi, A., Samimisedeh, P., Jafari Afshar, E., Mahmoudnia, S., Milan, N., Ayati, A., Madady, A., and Rastad, H. (2023). Neuromuscular diseases associated with COVID-19 vaccines: A systematic review and pooled analysis of 258 patients. BMC Neurol., 23.","DOI":"10.1186\/s12883-023-03486-y"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e34890","DOI":"10.1097\/MD.0000000000034890","article-title":"Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis","volume":"102","author":"Tayebi","year":"2023","journal-title":"Medicine"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Virgilio, E., Tondo, G., Montabone, C., and Comi, C. (2022). COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20010467"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.vaccine.2023.01.003","article-title":"CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series","volume":"41","author":"Ebrahimi","year":"2023","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","article-title":"A systematic review of cases of CNS demyelination following COVID-19 vaccination","volume":"362","author":"Ismail","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"104141","DOI":"10.1016\/j.msard.2022.104141","article-title":"Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations","volume":"68","author":"Kim","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"103739","DOI":"10.1016\/j.msard.2022.103739","article-title":"COVID-19 vaccine associated demyelination & its association with MOG antibody","volume":"60","author":"Netravathi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Rinaldi, V., Bellucci, G., Buscarinu, M.C., Renie, R., Marrone, A., Nasello, M., Zancan, V., Nistri, R., Palumbo, R., and Salerno, A. (2022). CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1018785"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13760-023-02373-0","article-title":"Spectrum of various CNS inflammatory demyelination diseases following COVID-19 vaccinations","volume":"124","author":"Salunkhe","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Albakri, K., Khaity, A., Atwan, H., Saleh, O., Al-Hajali, M., Cadri, S., Diab, R.A., Albazee, E., and Negida, A. (2023). Bell\u2019s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11020236"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1473-3099(21)00467-9","article-title":"The association between COVID-19 vaccination and Bell\u2019s palsy","volume":"22","author":"Cirillo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s13760-023-02245-7","article-title":"Risk and characteristics of Bell\u2019s palsy in adults as an adverse event following COVID-19 vaccination: A retrospective study","volume":"123","author":"Kim","year":"2023","journal-title":"Acta Neurol. Belg."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Abdelhady, M., Husain, M.A., Hawas, Y., Elazb, M.A., Mansour, L.S., Mohamed, M., Abdelwahab, M.M., Aljabali, A., and Negida, A. (2023). Encephalitis following COVID-19 Vaccination: A Systematic Review. Vaccines, 11.","DOI":"10.3390\/vaccines11030576"},{"key":"ref_128","first-page":"e31118","article-title":"A Possible Case of Autoimmune Encephalitis aftermRNA COVID-19 Booster Vaccine: A Case Report","volume":"14","author":"Dawood","year":"2022","journal-title":"Cureus"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.immuni.2020.12.011","article-title":"Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid","volume":"54","author":"Heming","year":"2021","journal-title":"Immunity"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Huang, Y.F., Ho, T.C., Chang, C.C., Shen, D.H., Chan, H.P., Chuang, K.P., Tyan, Y.C., and Yang, M.H. (2022). A Rare Adverse Effect of the COVID-19 Vaccine on Autoimmune Encephalitis. Vaccines, 10.","DOI":"10.3390\/vaccines10071114"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00415-021-10785-2","article-title":"Acute transverse myelitis following SARS-CoV-2 vaccination: A case report and review of literature","volume":"269","author":"Khan","year":"2022","journal-title":"J. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3988\/jcn.2022.18.1.114","article-title":"Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination","volume":"18","author":"Shin","year":"2022","journal-title":"J. Clin. Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.4103\/jfmpc.jfmpc_2394_21","article-title":"Small fiber neuropathy as a complication of SARS-CoV-2 vaccinations","volume":"11","author":"Finsterer","year":"2022","journal-title":"J. Family Med. Prim. Care"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"100304","DOI":"10.1016\/j.clinsp.2023.100304","article-title":"SARS-CoV-2 vaccination complicated by small fiber neuropathy, mast cell activation syndrome, and pericarditis","volume":"78","author":"Hertz","year":"2023","journal-title":"Clinics"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000528566","article-title":"Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment","volume":"15","author":"Mastropaolo","year":"2023","journal-title":"Case Rep. Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/mus.27251","article-title":"Post COVID-19 vaccine small fiber neuropathy","volume":"64","author":"Waheed","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"103129","DOI":"10.1016\/j.ajp.2022.103129","article-title":"Psychiatric adverse reactions to COVID-19 vaccines: A rapid review of published case reports","volume":"71","author":"Balasubramanian","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Kim, M.H., Choi, M.G., and Chun, E.M. (2024). Psychiatric adverse events following COVID-19 vaccination: A population-based cohort study in Seoul, South Korea. Mol. Psychiatry.","DOI":"10.1038\/s41380-024-02627-0"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Lazareva, M., Renemane, L., Vrublevska, J., and Rancans, E. (2024). New-onset psychosis following COVID-19 vaccination: A systematic review. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1360338"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.pedneo.2022.10.007","article-title":"Acute psychosis induced by mRNA-based COVID-19 vaccine in adolescents: A pediatric case report","volume":"64","author":"Lien","year":"2023","journal-title":"Pediatr. Neonatol."},{"key":"ref_141","unstructured":"WHO (2024, September 15). Adverse Events following Immunization. Available online: https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/aefi\/aefi."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jaut.1999.0346","article-title":"Vaccination and autoimmunity-v\u2019accinosis\u2019: A dangerous liaison?","volume":"14","author":"Shoenfeld","year":"2000","journal-title":"J. Autoimmun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/08830181003746304","article-title":"Could autoimmunity be induced by vaccination?","volume":"29","author":"Salemi","year":"2010","journal-title":"Int. Rev. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/eji.200939550","article-title":"Generating memory with vaccination","volume":"39","author":"Castellino","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"269","DOI":"10.34172\/bi.2023.27494","article-title":"SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and\/or bystander activation of the immune system","volume":"13","author":"Safary","year":"2023","journal-title":"Bioimpacts"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease","volume":"19","author":"Fujinami","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"103340","DOI":"10.1016\/j.autrev.2023.103340","article-title":"Insights into new-onset autoimmune diseases after COVID-19 vaccination","volume":"22","author":"Guo","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"25151355241228439","DOI":"10.1177\/25151355241228439","article-title":"Adjuvants in COVID-19 vaccines: Innocent bystanders or culpable abettors for stirring up COVID-heart syndrome","volume":"12","author":"Kanuri","year":"2024","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: Implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1056\/NEJMcibr2113694","article-title":"A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination","volume":"386","author":"Murphy","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.vaccine.2023.03.005","article-title":"Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management","volume":"41","author":"Ikewaki","year":"2023","journal-title":"Vaccine"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Sawant, J., Patil, A., and Kurle, S. (2023). A Review: Understanding Molecular Mechanisms of Antibody-Dependent Enhancement in Viral Infections. Vaccines, 11.","DOI":"10.3390\/vaccines11071240"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cyto.a.24047","article-title":"Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective","volume":"97","author":"Ulrich","year":"2020","journal-title":"Cytom. A"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/1756-185X.14238","article-title":"COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells","volume":"25","author":"Sachinidis","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Gutman, E.G., Fernandes, R.A., Raposo-Vedovi, J.V., Salvio, A.L., Duarte, L.A., Tardim, C.F., Costa, V.G.C., Pereira, V., Bahia, P.R.V., and da Silva, M.M. (2023). Molecular Mimicry between SARS-CoV-2 Proteins and Human Self-Antigens Related with Autoimmune Central Nervous System (CNS) Disorders. Microorganisms, 11.","DOI":"10.20944\/preprints202310.0052.v1"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Nunez-Castilla, J., Stebliankin, V., Baral, P., Balbin, C.A., Sobhan, M., Cickovski, T., Mondal, A.M., Narasimhan, G., Chapagain, P., and Mathee, K. (2022). Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. Viruses, 14.","DOI":"10.3390\/v14071415"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"103070","DOI":"10.1016\/j.jaut.2023.103070","article-title":"Molecular mimicry and autoimmunity in the time of COVID-19","volume":"139","author":"Rojas","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"eabj9256","DOI":"10.1126\/sciimmunol.abj9256","article-title":"COVID-19 vaccine side effects: The positives about feeling bad","volume":"6","author":"Sprent","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.15572","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources","volume":"20","author":"Greinacher","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Li, Z., Guo, J., and Bi, L. (2020). Role of the NLRP3 inflammasome in autoimmune diseases. Biomed. Pharmacother., 130.","DOI":"10.1016\/j.biopha.2020.110542"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.autrev.2018.01.020","article-title":"NLRP3: A promising therapeutic target for autoimmune diseases","volume":"17","author":"Shen","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e19341","DOI":"10.1016\/j.heliyon.2023.e19341","article-title":"In silico and in vitro inhibition of host-based viral entry targets and cytokine storm in COVID-19 by ginsenoside compound K","volume":"9","author":"Boopathi","year":"2023","journal-title":"Heliyon"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Landolina, N., Ricci, B., Veneziani, I., Alicata, C., Mariotti, F.R., Pelosi, A., Quatrini, L., Mortari, E.P., Carsetti, R., and Vacca, P. (2024). TLR2\/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1368946"},{"key":"ref_169","first-page":"e14296","article-title":"COVID-19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy","volume":"2014","author":"Lin","year":"2024","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Hajjo, R., Sabbah, D.A., Bardaweel, S.K., and Tropsha, A. (2021). Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines, 9.","DOI":"10.3390\/vaccines9101186"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pcad.2022.10.004","article-title":"Myocarditis associated with COVID-19 and its vaccines\u2014A systematic review","volume":"74","author":"Rout","year":"2022","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e2314291","DOI":"10.1001\/jamanetworkopen.2023.14291","article-title":"Evaluation of Autoantibody Binding to Cardiac Tissue in Multisystem Inflammatory Syndrome in Children and COVID-19 Vaccination-Induced Myocarditis","volume":"6","author":"Patel","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/ejhf.2669","article-title":"Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases","volume":"24","author":"Heidecker","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_174","first-page":"101280","article-title":"COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature","volume":"49","author":"Jaiswal","year":"2023","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e069445","DOI":"10.1136\/bmj-2021-069445","article-title":"Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following COVID-19 vaccination: Living evidence syntheses and review","volume":"378","author":"Pillay","year":"2022","journal-title":"BMJ"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2021.13443","article-title":"Myocarditis and Pericarditis afterVaccination for COVID-19","volume":"326","author":"Diaz","year":"2021","journal-title":"JAMA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cjca.2024.03.016","article-title":"Myocarditis and Pericarditis aftermRNA COVID-19 Vaccination: 2024 Status and Management Update","volume":"40","author":"McDonald","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"ref_178","first-page":"e44617","article-title":"COVID-19-Associated Acute Myocarditis: Risk Factors, Clinical Outcomes, and Implications for Early Detection and Management","volume":"15","author":"Kamath","year":"2023","journal-title":"Cureus"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/tomography8040164","article-title":"Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies","volume":"8","author":"Keshavarz","year":"2022","journal-title":"Tomography"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Puchalski, M., Kaminska, H., Bartoszek, M., Brzewski, M., and Werner, B. (2022). COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19063456"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e230044","DOI":"10.1148\/rg.230044","article-title":"Imaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination","volume":"43","author":"Marschner","year":"2023","journal-title":"Radiographics"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.radcr.2023.11.070","article-title":"COVID-19 mRNA vaccine-related myocarditis: A PRISMA systematic review, imaging approach and differential diagnoses","volume":"19","author":"Yeo","year":"2024","journal-title":"Radiol. Case Rep."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa030666","article-title":"A cluster of cases of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Tsang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7774\/cevr.2023.12.4.265","article-title":"COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review","volume":"12","author":"Suhaimi","year":"2023","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajem.2021.05.054","article-title":"Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines","volume":"49","author":"Long","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/vox.13633","article-title":"Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands","volume":"119","author":"Meier","year":"2024","journal-title":"Vox Sang."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Bahmanyar","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s10072-022-06000-3","article-title":"Central nervous system adverse events after ChAdOx1 vaccination","volume":"43","author":"Maramattom","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"106440","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106440","article-title":"Stroke Associated with COVID-19 Vaccines","volume":"31","author":"Kakovan","year":"2022","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s11739-021-02793-x","article-title":"Vaccine-induced thrombotic thrombocytopenia: The elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines","volume":"16","author":"Marcucci","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_192","first-page":"20480040231169464","article-title":"Cerebral venous sinus thrombosis following ChAdOx1 nCoV-19 AstraZeneca COVID-19 vaccine","volume":"12","author":"Sharma","year":"2023","journal-title":"JRSM Cardiovasc. Dis."},{"key":"ref_193","first-page":"e23507","article-title":"Vaccine-Induced Thrombotic Thrombocytopenia: A Case of Splanchnic Veins Thrombosis","volume":"14","author":"Abbasi","year":"2022","journal-title":"Cureus"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.7326\/M22-0988","article-title":"Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France","volume":"175","author":"Botton","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e246770","DOI":"10.1136\/bcr-2021-246770","article-title":"Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine","volume":"15","author":"Elkoumy","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13665","article-title":"COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome","volume":"107","author":"Franchini","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ijlh.13629","article-title":"Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia","volume":"43","author":"Favaloro","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamacardio.2021.3444","article-title":"Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review","volume":"6","author":"Rizk","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1056\/NEJMc2309016","article-title":"Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder","volume":"389","author":"Schonborn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Panagiota, V., Dobbelstein, C., Werwitzke, S., Ganser, A., Cooper, N., Sachs, U.J., and Tiede, A. (2022). Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia. Viruses, 14.","DOI":"10.3390\/v14081702"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2021012277","article-title":"Antiplatelet drugs block platelet activation by VITT patient serum","volume":"138","author":"Smith","year":"2021","journal-title":"Blood"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e2269","DOI":"10.1212\/WNL.0000000000012930","article-title":"Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis","volume":"97","author":"Misra","year":"2021","journal-title":"Neurology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-022-34068-0","article-title":"Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: A prospective cross-sectional study","volume":"13","author":"Etter","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Mundorf, A.K., Semmler, A., Heidecke, H., Schott, M., Steffen, F., Bittner, S., Lackner, K.J., Schulze-Bosse, K., Pawlitzki, M., and Meuth, S.G. (2024). Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS). Vaccines, 12.","DOI":"10.20944\/preprints202406.0848.v1"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s13311-021-01117-3","article-title":"Novel Immunological and Therapeutic Insights in Guillain-Barre Syndrome and CIDP","volume":"18","author":"Querol","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_206","first-page":"e2094","article-title":"Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study","volume":"101","author":"Bertrand","year":"2023","journal-title":"Neurology"},{"key":"ref_207","first-page":"2067","article-title":"Guillain-Barre syndrome following COVID-19 vaccination: A study of 70 case reports","volume":"86","author":"Sah","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Yang, Y., and Huang, L. (2023). Neurological Disorders following COVID-19 Vaccination. Vaccines, 11.","DOI":"10.3390\/vaccines11061114"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"577719","DOI":"10.1016\/j.jneuroim.2021.577719","article-title":"AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?","volume":"360","author":"Oo","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e936896","DOI":"10.12659\/AJCR.936896","article-title":"A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barre Syndrome","volume":"23","author":"Hilts","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"104758","DOI":"10.1016\/j.amsu.2022.104758","article-title":"Development of facial palsy following COVID-19 vaccination: A systematic review","volume":"82","author":"Khurshid","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00228-023-03510-7","article-title":"Seronegative acute encephalitis following COVID-19 vaccines: A case series of an overlooked diagnosis with literature review","volume":"79","author":"Mansour","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jns.12509","article-title":"Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature","volume":"27","author":"Abbott","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Petrenko, V.A., Gillespie, J.W., De Plano, L.M., and Shokhen, M.A. (2022). Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. Viruses, 14.","DOI":"10.3390\/v14020384"},{"key":"ref_215","first-page":"428","article-title":"Risk Factors Associated with Long COVID Syndrome: A Retrospective Study","volume":"46","author":"Akbari","year":"2021","journal-title":"Iran. J. Med. Sci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13643-023-02250-0","article-title":"A systematic review and meta-analysis of long COVID symptoms","volume":"12","author":"Natarajan","year":"2023","journal-title":"Syst. Rev."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"ofad233","DOI":"10.1093\/ofid\/ofad233","article-title":"Systematic Review of the Prevalence of Long COVID","volume":"10","author":"Woodrow","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_218","first-page":"960","article-title":"The partial pressure of isoflurane or halothane does not affect their solubility in rabbit blood or brain or human brain: Inhaled anesthetics obey Henry\u2019s Law","volume":"65","author":"Coburn","year":"1986","journal-title":"Anesth. Analg."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: Major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Gheorghita, R., Soldanescu, I., Lobiuc, A., Caliman Sturdza, O.A., Filip, R., Constantinescu-Bercu, A., Dimian, M., Mangul, S., and Covasa, M. (2024). The knowns and unknowns of long COVID-19: From mechanisms to therapeutical approaches. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1344086"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamainternmed.2023.0750","article-title":"Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis","volume":"183","author":"Tsampasian","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s12035-021-02696-0","article-title":"Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?","volume":"59","author":"Theoharides","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41392-021-00719-9","article-title":"SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-2600(23)00414-9","article-title":"The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: Staggered cohort study of data from the UK, Spain, and Estonia","volume":"12","author":"Catala","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.vaccine.2023.02.008","article-title":"Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis","volume":"41","author":"Watanabe","year":"2023","journal-title":"Vaccine"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"e000385","DOI":"10.1136\/bmjmed-2022-000385","article-title":"Effect of COVID-19 vaccination on long COVID: Systematic review","volume":"2","author":"Byambasuren","year":"2023","journal-title":"BMJ Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbi.2023.03.022","article-title":"COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis","volume":"111","author":"Ceban","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.eclinm.2022.101624","article-title":"Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review","volume":"53","author":"Notarte","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Romeiser, J.L., and Schoeneck, K. (2024). COVID-19 Booster Vaccination Status and Long COVID in the United States: A Nationally Representative Cross-Sectional Study. Vaccines, 12.","DOI":"10.3390\/vaccines12060688"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1017\/ash.2023.447","article-title":"The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: A systematic literature review and meta-analysis of the latest research","volume":"3","author":"Marra","year":"2023","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: Rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum. Cell"},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Wagner, R., Hildt, E., Grabski, E., Sun, Y., Meyer, H., Lommel, A., Keller-Stanislawski, B., Muller-Berghaus, J., and Cichutek, K. (2021). Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks. Vaccines, 9.","DOI":"10.3390\/vaccines9070747"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5582\/ddt.2021.01064","article-title":"Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021","volume":"15","author":"Cui","year":"2021","journal-title":"Drug Discov. Ther."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1017\/S0266462322000071","article-title":"European Network for Health Technology Assessment\u2019s Response to COVID-19: Rapid Collaborative Reviews on Diagnostic Tests and Rolling and Rapid Collaborative Reviews on Therapeutics","volume":"38","author":"Ballini","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s43441-022-00383-3","article-title":"Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?","volume":"56","author":"Klein","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_236","unstructured":"WHO (2024, September 15). COVID-19 Advice for the Public: Getting Vaccinated. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/10\/1320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:15:17Z","timestamp":1760112917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/10\/1320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":236,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["biom14101320"],"URL":"https:\/\/doi.org\/10.3390\/biom14101320","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}